Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: A3 Adenosine Receptor (A3AR) Agonists as an Orally-Administered Analgesic for Treatment of Chronic Neuropathic Pain

Riepilogo

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to BioIntervene, Inc., a company having a place of business in Saint Louis, Missouri to practice the inventions embodied in the following patent applications and patents: 1. U.S. Patent 8,735,407, issued May 27, 2014, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-US-06]; 2. European Patent Application 09728154.7, filed March 24, 2009, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-EP-05]; 3. Canadian Patent Application 2720037, filed March 24, 2009, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-CA-04]; 4. Australian Patent 2009231978, issued February 20, 2014, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-AU-03]; 5. U.S. Patent Application 13/371,081, filed February 10, 2012, titled "A3 Adenosine Receptor Agonists And Antagonists" [HHS Ref.